Marks, María Paula
Giménez, Carla Alejandra
Isaja, Luciana
Vera, Mariana Belén
Borzone, Francisco Raúl
Pereyra-Bonnet, Federico
Romorini, Leonardo
Videla-Richardson, Guillermo Agustín
Chasseing, Norma Alejandra
Calvo, Juan Carlos
Vellón, Luciano http://orcid.org/0000-0001-8531-6503
Funding for this research was provided by:
National Cancer Institute
National Research Council (PIP300, 2014-2016, Argentina)
Alberto J. Roemmers Foundation, Argentina
Florencio Fiorini Foundation, Argentina
Honorio Bigand Foundation, Argentina
Rene Baron Foundation, Argentina
Williams Foundation, Argentina
National Research Council-CONICET, Argentina
Article History
Received: 21 November 2023
Accepted: 4 January 2024
First Online: 28 February 2024
Declarations
:
: Carla Alejandra Gimenez and Federico Pereyra-Bonnet are partners at CASPR Biotech, Buenos Aires—Argentina, San Francisco—USA. The other authors have no conflict of interest.
: The present work does not involve samples from patients, aside from those from public access databases, only cell lines available commercially or upon request. However, it has been submitted and approved by the “Dr. Enrique Segura” Ethics Committee from the IBYME when required by funding institutions. The stem cell lines used in this work have previously been generated and published by co-authors in this paper (stated in the references section). All methods in the present work were carried out in accordance with relevant guidelines and regulations.
: All the authors agreed to the publication of the present manuscript.